A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Summary

Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.

Timeline

Start

2005-11

Primary completion

2009-01

Completion

2009-01

Outcome

Outcome not reported

Stopped: “could not find subject population”

Drugs

Indications